Fourth Quarterly Performance Report Released for the 2018-2019 Fiscal Year

The Quarterly Performance Report for the fourth quarter of the 2018-2019 fiscal year is now available online. Continue reading

Important notice regarding Inveltys

The board approved Inveltys (loteprednol etabonate ophthalmic suspension) 1% for addition to Rule 64B13-18.002. Effective August 5, 2019, Licensees are now permitted to prescribe Inveltys. Continue reading

Brand Names not allowed on formulary.

The Board of Optometry met on July 18, 2019 in Orlando regarding adding Rocklatan to the formulary. Click here for more information on the formulary. Continue reading

Human Trafficking

Click here for new profession requirements and reporting procedures regarding Human Trafficking Continue reading

Nonopioid Alternatives Pamphlet

Click here to access the pamphlet for “Information on Nonopioid Alternatives for the Treatment of Pain” Continue reading

Telehealth

Click here for information on the new law that sets standards of practice and authorizes out-of-state health care practitioners to perform telehealth services for patients in Florida. Continue reading

Third Quarterly Performance Report Released for the 2018-2019 Fiscal Year

The Quarterly Performance Report for the third quarter of the 2018-2019 fiscal year is now available online. Continue reading

Board Chairs/Vice Chairs Annual Long-range Planning Meeting

The Annual Long Range Planning meeting has been scheduled for Friday, October 18, 2019. Please click here for more information. Continue reading

New Legislation Impacting Your Profession

Click here to view a full list of bill summaries from the 2019 Florida Legislative Session that may impact your profession. Continue reading

Important notice regarding Rhopressa

The board approved Rhopressa (netarsudil ophthalmic solution) 0.02% for addition to Rule 64B13-18.002. Effective January 25, 2019, Licensees are now permitted to prescribe Rhopressa. Continue reading